Saliogen Therapeutics, Inc. — Form D/A
Saliogen Therapeutics, Inc. of CAMBRIDGE, MA, a company, filed a Form D amendment with the SEC on 2022-04-18. The offering totals $132.2M, of which $132.2M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2022-04-18
- Form: D/A
- Accession: 0001213900-22-020351
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $132.2M
- Amount sold: $132.2M
- Investors: 24
- Date of first sale: 2021-11-24
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-423901
Issuer
- Name: Saliogen Therapeutics, Inc.
- CIK: 0001845309
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2020
- Address: 245 FIRST STREET, CAMBRIDGE, MA, 02142
- Phone: (857) 990-2200
Officers, directors & promoters (7)
| Name | Role | Location |
|---|
| CRAIG GORDON | Director | NOVATO, CA |
| Joseph Higgins | Director | Cambridge, MA |
| Sukumar Nagendran | Director | NOVATO, CA |
| Sean Stalfort | Director | Charlottesville, VA |
| Raymond Tabibiazar | Director | Cambridge, MA |
| Joseph Higgins | Executive Officer | Cambridge, MA |
| Raymond Tabibiazar | Executive Officer | Cambridge, MA |
Other filings by this issuer (2)
More